With FDA’s clearance of the new Vitros 7600 integrated system from Ortho Clinical Diagnostics, the company introduces Digital Chemistry technology to clinical lab management in the United States.

Ortho’s Digital Chemistry technology combine’s the company’s proprietary MicroSlide technology with sophisticated digital imaging capabilities, and the potential to perform two separate lab tests simultaneously. Digital Chemistry brings powerful data intelligence, operational improvements, and heightened quality to the lab. Such enhancements help clinical laboratories keep pace with a rapidly evolving global healthcare environment, without requiring additional lab space.


Jennifer Paine, Ortho Clinical Diagnostics.

“It’s an exciting time for clinical labs, and today’s clearance of Ortho’s Vitros XT 7600 system represents a fundamental improvement in the way labs can operate, now and in the future,” says Jennifer Paine, Ortho’s chief product portfolio officer. “Vitros XT 7600, along with Digital Chemistry, harnesses the power of our proprietary dry slide technology to deliver high-quality test results and higher throughput—all within the lab’s existing physical footprint.”

The Digital Chemistry behind Ortho’s Vitros XT 7600 is based on three enabling technologies:

  • Digital imaging technology. Advanced optics glean significantly more information from testing than before, improving performance and enabling powerful data analysis.
  • MicroSlide. A full testing environment on a postage-stamp-sized piece of film, enabling precise and accurate testing.
  • Dry technology. Unlike traditional wet chemistry systems, whose operation requires highly purified water and complex plumbing systems, tests using Ortho’s proprietary dry-slide technology can be performed without water. This eliminates the risk that poor water quality could affect test results.

“Ortho’s MicroSlide, paired with Intellichek monitoring, allows me to sleep at night, because I know the results reported by our technologists on more than 1,000 patients nightly are accurate,” says Jaime Calnan, laboratory manager at Central Ohio Primary Care Physicians. “We have been an Ortho customer for more than 10 years, and we welcome this new innovation.”

In addition, Ortho’s Vitros XT 7600 will introduce multitest processing—the potential to offer two tests per slide instead of one—to clinical chemistry. Now under development, multitest processing is expected to enable the instrument to simultaneously perform pairs of tests that are frequently ordered together for the same patient. This saves time and space in the lab, and increases productivity, while also requiring less patient sample for testing—an important advantage for vulnerable patients or those with venous access issues.

The Ortho Vitros XT 7600 integrated system has received FDA clearance for the US market, and will be available for purchase in the first quarter of 2019. The product is currently available for purchase in Canada and numerous countries in Europe, the Middle East, Africa, Asia, and Latin America.

For further information, visit Ortho Clinical Diagnostics.

Featured image: The Vitros XT 7600 integrated analyzer from Ortho Clinical Diagnostics.